Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEPSTONE: Ozanimod Induction in Crohn's Disease
NCT02531113Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2015
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of ozanimod in Crohn's disease, sponsored by Celgene Corporation. Started Oct 2015; status: completed.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02531113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531113.